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ABSTRACT 1 
Over the last 20 years, there has been increasing interest in the occurrence, fate, 2 
effects and risk of pharmaceuticals in the natural environment. However, we still have 3 
only limited or no data on ecotoxicological risks of many of the active pharmaceutical 4 
ingredients (APIs) currently in use. This is partly due to the fact that the environmental 5 
assessment of an API is an expensive, time-consuming and complicated process. 6 
Prioritisation methodologies, that aim to identify APIs of most concern in a particular 7 
situation, could therefore be invaluable in focusing experimental work on APIs that really 8 
matter. The majority of approaches for prioritising APIs require annual pharmaceutical 9 
usage data. These methods cannot therefore be applied to countries, such as Kazakhstan, 10 
which have very limited data on API usage. This paper therefore presents an approach for 11 
prioritising APIs in surface waters in information-poor regions such as Kazakhstan. 12 
Initially data were collected on the number of products and active ingredients for different 13 
therapeutic classes in use in Kazakhstan and on the typical doses. These data were then 14 
used alongside simple exposure modelling approaches to estimate exposure indices for 15 
active ingredients (about 240 APIs) in surface waters in the country.  Ecotoxicological 16 
effects data were obtained from the literature or predicted. Risk quotients were then 17 
calculated for each pharmaceutical based on the exposure and the substances ranked in 18 
order of risk quotient. Highest exposure indices were obtained for benzylpenicillin, 19 
metronidazole, sulbactam, ceftriaxone and sulfamethoxazole. The highest risk was 20 
estimated for amoxicillin, clarithromycin, azithromycin, ketoconazole and 21 
benzylpenicillin. In the future, the approach could be employed in other regions where 22 
usage information are limited. 23 
Key words: active pharmaceutical ingredients, ecotoxicity, Kazakhstan, exposure, 24 
environmental risk 25 
 3 
INTRODUCTION 26 
Active pharmaceuticals ingredients (APIs) can be released to the aquatic 27 
environment during their manufacture, following use and as a result of disposal (Boxall et 28 
al. 2003). The major pathway is thought to be through excretion to the sewage system 29 
where they are then transported to wastewater treatment plants (WWTPs) (Boxall et al. 30 
2012). As many APIs are resistant to treatment in WWTPs, they are ultimately released in 31 
WWTP effluents into surface waters. A range of APIs has been detected in surface waters 32 
and wastewater effluents in several regions of the globe, including the Arctic (Besse et al. 33 
2008; Brausch and Rand 2011). Around 160 different APIs have been detected in the 34 
aquatic environment with the most common classes being detected belonging to the 35 
antibiotic, analgesic, painkiller and cardiovascular drug families (Kummerer 2010).  36 
A wide range of effects of pharmaceuticals on aquatic organisms have been reported 37 
(Hegelund et al. 2004; Porsbring et al. 2009; Shi et al. 2012). Chronic toxicity studies have 38 
shown effects at low concentrations in fish, invertebrates, algae and bacteria. For example, 39 
diclofenac has been reported to have adverse histological impacts on kidney and gills of 40 
rainbow trout at concentrations of 5 µg/L in 28 days (Schwaiger et al. 2004). 41 
Acetaminophen, venlafaxaine, carbamazepine and gemfibrozil at concentrations  of 10 42 
Pg/L 0,5 Pg/L and 10 Pg/L respectively, had an adverse reproductive impacts, inducing 43 
reproduction and changing kidney proximal tubule morphology (Galus et al. 2013). 44 
Concentrations of propranolol and fluoxetine seen in effluents have been shown to affect 45 
reproduction in aquatic organisms and the nervous system in fish (Kummerer 2010).  46 
While a wealth of data is now available on the occurrence, fate and effects of APIs 47 
in the natural environment, the knowledge of the risk of pharmaceuticals in water is still 48 
limited. One of the major challenges is that while over 1500 APIs are in use, we only have 49 
data on the environmental risks of a few of these (Berninger et al. 2016). Therefore, 50 
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approaches are needed that cut down the number of pharmaceuticals to be studied in order 51 
to focus on substances that are likely to pose the greatest risk and and for which 52 
environmental risk should therefore be established using experimental testing (Besse et al. 53 
2008; Guo et al. 2016). 54 
Prioritization methods provide an approach to help to focus research on APIs that 55 
really matter (Roos et al. 2012). A variety of approaches have therefore been proposed and 56 
applied for ranking of activated pharmaceutical ingredients (APIs). Mostly these 57 
approaches cover areas of Western Europe and North America (Besse et al. 2008; Roos et 58 
al. 2012; Guo et al. 2016). Typically, these approaches use information on API usage to 59 
assess likely exposure concentrations and compare these to predictions of potential 60 
toxicity. However, only a few studies have prioritised APIs in other regions of the world 61 
such as Eastern Europe, Africa and South America (e.g. Al-Khazrajy and Boxall 2016). 62 
Prioritization of pharmaceuticals in these regions is more challenging as information on 63 
API usage is either limited or non-existent for many of these regions.  64 
It is however important to understand the risks of drugs in the environment in these 65 
other unstudied regions. For example, in Kazakhstan, the focus of this study, the 66 
pharmaceutical market in the country is rapidly growing, and in 2012 more than 500 67 
million packages of drugs were sold in the country corresponding to an average of 32 68 
packages per person per year (Tashenov and Cherednichenko 2013). Medical substances 69 
are readily available in Kazakhstan with most of them being freely available for purchase 70 
over the counter. According to the Ministry of Healthcare and Social Development of the 71 
Republic of Kazakhstan, there are 7713 registered medications and approximately 24% of 72 
these are available without a prescription (MHSD 2016). Wastewater treatment systems in 73 
Kazakhstan are also old and employ old technologies so the treatment may not be as 74 
effective in removing APIs as in western countries. Consequently, emissions of 75 
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pharmaceuticals to the natural environment in Kazakhstan are expected to be high and 76 
impacts could be greater than elsewhere in the World. 77 
The aim of this study was therefore to develop an approach for prioritizing 78 
pharmaceuticals in surface water in regions with limited data and to apply the approach to 79 
identify APIs in use in Kazakhstan that require further scrutiny in terms of the assessment 80 
of their potential risks to the aquatic environment of Kazakhstan.  81 
METHODS  82 
The study aimed to identify those APIs most likely to lead to environmental impacts  83 
in Kazakhstan. The overall approach to prioritisation is illustrated in Figure 1. The 84 
approach was designed to consider potential for impacts of apical endpoints (mortality, 85 
growth and reproduction) in aquatic systems in Kazakhstan as well as impacts on possible 86 
non-apical endpoints corresponding to the therapeutic mode of action of an API. 87 
Identification of pharmaceuticals in use in Kazakhstan and selection APIs for detailed 88 
assessment 89 
A list of APIs in use in Kazakhstan was constructed using the online directory of 90 
pharmaceutical products in use Kazakhstan (Vidal-Kazakhstan LLP 2015). For each API, 91 
the number of products on the market was determined. Vitamins and vaccines were 92 
excluded from the analysis. To make the prioritisation manageable, all compounds 93 
contained in fewer than 3 products were not considered further as it was assumed that 94 
exposure to these would be low, although in the future these compounds could also be 95 
assessed. For the remaining compounds, data on the the recommended daily dose and 96 
treatment duration was obtained (Supporting information, Table 1). 97 
Environmental exposure  98 
The relative exposure of those APIs in use in three or more products was 99 
characterised by estimating an Exposure Index for surface water (EIsw).  The EI was 100 
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calculated by multiplying the number of products containing an API available on the 101 
market, the average daily dose and fraction of drug not-metabolised by the patient and the 102 
fraction not removed by the WWTP. The fraction of unmetabolised API was obtained 103 
from peer-reviewed papers and available online databases (Wishart et al. 2006; FASS 104 
2011; Medsafe 2015; Drugs.com 2016) (Supporting information, Table 2). The 105 
compounds without data were considered to be totally excreted from the body. The 106 
fraction not removed by the WWTP was estimated using an equation proposed by the 107 
Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use 108 
(ECA 2003), with slight modification (Eqn.1): 109 
 110 
Fwwtp= 1 - 
ୗ୪୳ୢ୥ୣ୧୬୦ୟୠכ୏୭ୡכ୤୭ୡୱ୪୳ୢ୥ୣ୛ୟୱ୲ୣ୛୧୬୦ୟୠାሺୗ୪୳ୢ୥ୣ୧୬୦ୟୠכ୏୭ୡכ୤୭ୡୱ୪୳ୢ୥ୣሻ  (Eqn. 1) 111 
 112 
Where, Fwwtp is the fraction of pharmaceutical released from the WWTP. 113 
Wastewater parameters were obtained from the EU Technical Guidance Document for risk 114 
assessment of chemicals (EC, 2003) as these are widely recognised for use in risk 115 
assessment. WasteWinhhab is the amount of wastewater per inhabitant per day, that was 116 
assumed to be 200 L/day (ECA 2003). Sludgeinhab was mass of waste sludge per 117 
inhabitant per day which was assumed to be 0.074 kg inh/day (ECA 2003). The  focsludge 118 
(fraction of sludge organic carbon) was assumed to be 0.326 (Struijs et al. 1991). The soil 119 
organic carbon-water partitioning coefficient (Koc) value was estimated with the model 120 
established for ionizable organic chemicals proposed by Franco and Trapp (2008). This 121 
model estimates sorption using information on the hydrophobicity and degree of 122 
dissociation of a molecule using the following equations: 123 
 124 
Log Koc  ORJĭnXͳͲ଴Ǥହସ୪୭୥୔୬ାଵǤଵଵĭionͳͲ଴Ǥଵଵ୪୭୥୔୬ାଵǤହସ)                       for acids (Eqn. 2) 125 
 7 
Log Koc  ORJĭnXͳͲ଴Ǥଷ଻୪୭୥୔୬ାଵǤ଻଴ĭion10pKa0.65 Xf0.14)                         for bases (Eqn. 3) 126 
 127 
An Exposure Index representing the internal exposure of APIs in fish plasma (EIfish) 128 
was also determined by multiplying the EIsw by the fish blood-water partition coefficient 129 
(Pbw) for each API. The calculation of Pbw was performed using the equation proposed 130 
by Fick et al. (2010) (Eqn. 4): 131 
 132 
LogPbw = 0.73 * LogKow ± 0.88   (Eqn. 4) 133 
 134 
Where Pbw was aqueous phase and fish arterial blood partition coefficient and Kow 135 
was Octanol/water partition coefficient.  136 
Apical effects assessment 137 
Predicted no-effect concentrations (PNEC) were estimated for each API using 138 
Equation 5. In order to estimate PNECs, we collected all available experimental 139 
ecotoxicological data on the toxicity of APIs to apical endpoints in aquatic organisms from 140 
peer-reviewed papers, using Google scholar, Web of Knowledge and SCOPUS, and online 141 
datasets (FASS 2011) (Supporting information, Table 3). The data contained acute and 142 
chronic ecotoxicity endpoints as LC/EC50 values and, as the aim of this work for 143 
priotisation and not regulation, were not quality assessed. For substances that did not have 144 
experimental ecotoxicity data, the quantitative structure activity relationships (QSAR) 145 
toolbox was used in order to fill all gaps (OECD 2009). This software helped to define 146 
potential analogues and construct a matrix of data based on them. Initially, we selected the 147 
protein-binding profile. Then, on endpoints section we selected ecotoxicological 148 
information, that included growth, immobilisation and mortality. After that, on the 149 
category definition module we used the aquatic toxicity classification system by 150 
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ECOSAR. Finally, the toolbox processed data with a common structure (70-90%). Where 151 
the toolbox identified predictions to not be accurate, these predictions were not included in 152 
the priotization analysis.  153 
 154 
PNEC = ୉ୡ୭୘୭୶୅୊    (Eqn. 5) 155 
 156 
Where PNEC is the predicted no-effect concentration, EcoTox is the most sensitive 157 
ecotoxicological data for the aquatic compartment and AF was the safety factor. The AF 158 
was selected based on recommendations in the Technical guidance document on risk 159 
assessment (ECA 2003). 160 
Non-Apical Endpoints 161 
In order to account for non-apical effects relating to the therapeutic mode of action 162 
of each API, we used a similar approach to that proposed by Huggett et al. (2003) and 163 
collated information on plasma therapeutic concentrations (HtPC) of each API in humans. 164 
The information of HtPC was obtained from online databases (FASS 2011; Medsafe 2015; 165 
Drugs.com 2016; Kim et al. 2016) (Supporting information, Table 4).   166 
Ranking APIs 167 
The final step in the study was prioritization of the APIs. Risk Scores were used to 168 
rank compounds. Basically, the score was estimated by dividing the exposure indices for 169 
water and fish by either the PNEC or the HtPC. APIs with the highest ranking score were 170 
classified as the substances that should be in the list of concern. 171 
RESULTS 172 
In total, there are 7713 pharmaceutical products in use in Kazakhstan containing 173 
1684 APIs. When complex mixtures as well as vaccines and vitamins are excluded,  841 174 
APIs remained. The top 20 APIs, based on product number containing the ingredient, are 175 
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shown in Figure 2. Assuming product number is a surrogate for the extent of use, the most 176 
widely used compound is paracetamol (an analgesic) followed by hydrochlorothiazide (a 177 
diuretic used to treat high blood pressure, swelling and fluid build up)  and metronidazole 178 
(an antibiotic).  179 
When APIs in use in fewer than three products were excluded, a list of 237 APIs 180 
was obtained for further prioritisation. Exposure indices for these substances are provided 181 
in the Supporting Information(Supporting information Tables 2 and 4). The  highest 182 
exposure indices in surface water were seen for benzylpenicillin, metronidazole, 183 
sulbactam, ceftriaxone and sulfamethoxazole, whereas the highest exposure indices in fish 184 
plasma were seen for lisinopril, orlistat, telmisartan, drotaverine and terbinafine. 185 
Experimental ecotoxicity data for daphnia, fish and/or algae was available for 154 of 186 
the 237 APIs and human plasma therapeutic concentration data were available for 201 of 187 
these. Therefore, for the prioritisation, experimentally-based PNECs were used for 70% of 188 
compounds and QSAR-based PNECs were used for 66 compounds. The most highly 189 
ranked substances based on the apical ecotoxicological endpoints were amoxicillin, 190 
clarithromycin, azythromycin, ketoconazole and benzylpenicillin, whereas the most highly 191 
ranked compounds based on the non-apical assessment were lisinopril, orlistat, estradiol 192 
valerate, drotaverine and estradiol. Table 1 shows the top five ranked compounds broken 193 
down by classification of diseases. Classification of diseases was based on classes of 194 
illness cases registrated in health care institutions in Kazakhstan in 2014 (MHSD 2015).   195 
DISCUSSION 196 
The objective of the present study was to develop a method for ranking 197 
pharmaceuticals in data-poor regions. The approach built on previous studies but, as usage 198 
amount data were not available for Kazakhstan, used information on product numbers as 199 
the basis for the exposure characterisation. The assumption being that APIs which were 200 
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present in numerous products would be more widely used than APIs present in only a few 201 
products. During the study we found the main drugs of concern, based on a combination of 202 
risk to apical or non-apical endpoints, in Kazakhstan were amoxicillin, clarithromycin, 203 
azithromycin, ketoconazole, benzylpenicillin, terbinafine, drotaverine, diclofenac, 204 
benzathine benzylpenicillin and telmisartan as these had the highest risk scores. 205 
Even though the ranking approach used a different approach from previous studies, the 206 
results show that some of the top ranked compounds in our study are also ranked highly by 207 
earlier prioritization research (Table 2).  For example, amoxicillin, clarithromycin, 208 
diclofenac and azithromycin,  with the highest  risk score,  were defined  as  high priority  209 
in an ecotoxicological risk-based prioritization study performed in the UK by Guo et al. 210 
(2016). Moreover, amoxicillin  was detected as a chemical with the highest hazard to 211 
aquatic organisms in the United Kingdom, France, Italy, Iran, Korea and Spain (Table 2).  212 
Cooper et al. (2008) concluded that sulfamethoxazole, diclofenac and clarithromycin were 213 
the pharmaceuticals of high risk in a US study. Ketoconazole was identified as one of the 214 
priority substance in a study by Roos et al. (2012) in Swedish aquatic systems. Lisinopril, 215 
orlistat, estradiol valerate, cinnarizine, drotaverine, estradiol and clotrimazole were 216 
identified as having the potential to elicit subtle effect in fish. Estradiol was identified by 217 
Guo et al. (2016) as having the potential to cause subtle effects in fish.  218 
Most of the pharmaceuticals ranked highly on our list are related to the treatment of 219 
infectious and parasitic diseases, so the majority of them are antibiotics. Currently, 220 
antibiotics are one of the most well investigated pharmaceutical classes in terms of acute 221 
toxicity to aquatic organisms (Brausch and Rand 2011). Nevertheless, we still have a 222 
limited dataset on chronic effects of many antibiotics to aquatic ecosystems. The majority 223 
of ecotoxicology studies have been focusing on acute toxicity of antibiotics to algal 224 
species and the EC50s vary from 0.002 mg/L to 1283 mg/L (Guo et al. 2015).  225 
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Most of drugs from our ranking list have been detected in monitoring studies around 226 
the world. This provides a level of confidence in the approach. For instance, amoxicillin 227 
was detected in concentrations of 28 Pg/L and 82.7 Pg/L in hospital wastewater in 228 
Germany during the daytime (Kummerer 2001). Yasojima et al. (2006) showed 229 
clarithromycin and azithromycin at concentrations 647 ng/L and 260 ng/L in the 230 
wastewater effluents in Japan. 231 
The majority of substances from the ranking list have been reported to cause toxicity 232 
to aquatic organisms. For instance, Shi et al. (2012) showed that clotrimazole can affect 233 
the development stage of X. tropiclalis larvae and can lead to mortality of X. tropiclalis 234 
even at a low concentration (0.1 µg/L). In 2008 Porsbring et al. (2009) conducted a 235 
toxicity assessment of clotrimazole to natural microalgal communities. The results of the 236 
research showed that this compound causes growth inhibition of algal communities, it can 237 
alter their pigment profiles and physiology (Porsbring et al. 2009). Hegelund et al. (2004) 238 
investigated the response of fish to ketoconazole. Their results showed, that this 239 
compound had effects to rainbow trout and killifish at 12 and 100 mg/kg, as it suppressed 240 
cytochrome enzyme activity of fish (Hegelund et al. 2004). Halling-Sorensen (2000) 241 
showed that benzylpenicillin was toxic to M.aeruginasa, with an EC50 value of 0.005 242 
mg/L. There is a large volume of published studies describing the risk of clarithromycin to 243 
the environment. For instance, Oguz and Mihciokur (2014) studied the environmental 244 
risks of drugs in Turkey and concluded that clarithromycin can cause potential hazard to 245 
living organisms because of its high bioconcentration factor. Furthermore, the substance 246 
with the highest concentration in Italian rivers was clarithromycin at a concentration of 247 
0.02 µg/L (Calamari et al. 2003). A considerable amount of literature has been published 248 
on the toxicity and occurrence of diclofenac in the last decades. Recent research by Acuna 249 
et al. (2015) has reported that the occurrence of diclofenac was mentioned in 142 papers, 250 
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which covered 38 countries. Moreover, there were 156 reports about the ecotoxicological 251 
effects of this substance (Acuna et al. 2015).  252 
LIMITATIONS 253 
The prioritization results in the present study are based on information on the number 254 
of products as we were not able to obtain information on annual mass usage data. The use of 255 
consumption data of drugs could give us more precise results but simply is not available in 256 
countries like Kazakhstan. In future, we recommend that more efforts are put into the 257 
development of databases on annual usage of pharmaceuticals (and other) chemicals in 258 
Kazakhstan and other regions with lack of data. In order to calculate PNEC, ecotoxicological 259 
data were collected from different sources and were not rated for data quality. Moreover, the 260 
majority of pharmaceuticals excreted to WWTPs would be in the form of metabolites. The 261 
paper did not consider these for ranking even though in some instances they could pose a risk 262 
to the environment.  263 
CONCLUSION 264 
The population of Kazakhstan is increasing so it is likely that consumption of 265 
medicines in the country will grow too. Pharmaceuticals are readily available in Kazakhstan 266 
with most of them being freely available for purchase over the counter. Wastewater treatment 267 
systems in the country are also old and employ old technologies so the treatment may not be 268 
as effective as in Western countries. Consequently, emissions of pharmaceuticals to the 269 
natural environment in Kazakhstan are expected to be high and impacts could be greater than 270 
elsewhere in the world. Overall, the present assessment prioritized the human prescription 271 
APIs, that are most likely to be present in Kazakhstan surface waters and which could pose 272 
the greatest risk to living organisms. We recommend that these compounds be considered in 273 
future research to monitor concentrations of the APIs in the Kazakhstan environment and to 274 
establish the level of risk to ecosystems in the country. It would be interesting to consider 275 
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about the effect mixture pharmaceuticals on surface water. While the paper has focused on 276 
prioritisation of pharmaceuticals in use in Kazakhstan, the design of the approach means that 277 
it can be applied in other countries with limited data on API usage. The approach could 278 
therefore be invaluable in determining the wider impacts of APIs across the globe.  279 
 280 
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Figure captions 
 
Figure 1. Outline of the prioritization approach for active pharmaceutical ingredients (APIs) 
in surface waters in Kazakhstan. APIs ± active pharmaceuticals ingredients; WWTP ± 
wasterwater treatment plant; EIsw ± exposure index for surface water; PNEC ± predicted no-
effect concentration; RCR ± risk score ratio; EIfish ± exposure index in fish plasma; HtPC ± 
human plasma therapeutic concentration. 
Figure 2. Top 20 active pharmaceutical ingredients in use in Kazakhstan based on number 
of products containing an active pharmaceuticals ingredients. 
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Table 1. Summary of top ranked APIs, by disease class, prioritised based on apical effects 
(EIsw:PNEC) and non-apical effects (HtPC:EIfish). Compounds in bold have been identified 
as priority using both methods. 
# Classification 
of diseases 
Registered 
morbidity 
incidents in 
health care 
institutions 
in 2014 in 
Kazakhstan 
(per 
100000) 
Top ranked APIs 
(EIsw:PNEC) 
Top ranked APIs 
(HtPC:EIfish) 
1 Respiratory 
diseases 
28233.8 Xylometazoline 
Beclomethasone 
Chloropyramine 
Pheniramine 
Clemastine 
Loratadine 
Clemastine 
Montelukast 
Dextromethorphan 
Fexofenadine 
2 Diseases of 
blood 
circulatory 
system  
13472.7 Telmisartan 
Atorvastatin 
Rutoside 
Losartan 
Captopril 
Lisinopril 
Telmisartan 
Amiodarone 
Rosuvastatin 
Amlodipine 
3 Diseases of 
digestive 
system 
8952.1 Drotaverine 
Ursodeoxycholic 
acid 
Thioctic acid 
Orlistat 
Drotaverine 
Repaglinide 
Loperamide 
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Bisacodyl 
Pioglitazone 
Hyoscine 
butylbromide 
4 Disease of 
urino-genital 
system 
7250.8 Ketoconazole 
Levonorgestrel 
Nystatin 
Miconazole 
Drospirenone 
Estradiol valerate 
Estradiol 
Miconazole 
Ethinylestradiol 
Ketoconazole 
5 Diseases of the 
eye and its 
appendages 
5516.3 Neomycin  
Betaxolol 
Tropicamide 
Betaxolol 
Neomycin  
Tropicamide 
6 Diseases of the 
blood-forming 
organs and 
certain 
4965.9 
 Clopidogrel Clopidogrel 
7 Diseases of 
nervous system 
4471.6 Cinnarizine 
Paracetamol 
Betahistine 
Carbamazepine 
Gabapentin 
Cinnarizine 
Fentanyl 
Acetylsalicylic 
acid 
Tramadol 
Valproic acid 
8 Diseases of the 
musculoskeletal 
system and 
connective 
tissue 
4093.1 Diclofenac 
Etofenamate 
Ketoprofen 
Clodronic acid  
Naproxen 
Methyl salicylate 
Diclofenac 
Indomethacin 
Benzydamine 
Ketoprofen 
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9 Infectious and 
parasitic 
diseases 
2296 Amoxicillin 
Clarithromycin 
Azithromycin 
Benzylpenicillin 
Terbinafine 
Clotrimazole 
Isotretinoin 
Disulfiram 
Terbinafine 
Azithromycin 
10 Tumors 1657. Oxaliplatin 
Cisplatin  
Mycophenolic acid 
Capecitabine 
Paclitaxel 
Paclitaxel 
Mycophenolic 
acid 
Imatinib 
Anastrozole 
Topotecan 
11 Mental and 
behavioral 
disorders 
1270.6 Citicoline  
Piracetam 
Fluoxetine 
Clozapine 
Sertraline 
Sertraline 
Fluoxetine 
Chlorpromazine 
Risperidone 
Clozapine 
Note: Bold highlighted pharmaceuticals show their common appearance in top ranking of 
drugs on both risk ratios. APIs ± activated pharmaceuticals ingredients; EIsw ± exposure 
index for surface water; PNEC ± predicted no-effect concentration; HtPC ± human plasma 
therapeutic concentration; EIfish ± exposure index in fish plasma. 
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Table 2. Defined top priority APIs in surface water of Kazakhstan, UK, France, US, Sweden, Iran, Korea and Spain 
Kazakhstan  United 
Kingdom (Guo 
et al. 2016) 
France (Besse 
et al. 2008)  
United States 
(Cooper et al. 
2008) 
Sweden 
(Roos et al. 2012) 
Iran 
(Alighardas
hi et al. 
2014) 
Korea  
(Kim et al. 
2008) 
Italy (Zuccato 
et al. 2005) 
Amoxicillin 
Clarithromycin 
Azithromycin 
Ketoconazole 
Benzylpenicillin 
Terbinafine 
Drotaverine 
Diclofenac 
Benzathine 
benzylpenicillin  
Telmisartan 
Amitriptyline 
Amoxicillin 
Atorvastatin 
Azithromycin 
Carbamazepine 
Ciprofloxacin 
Clarithromycin 
Diclofenac 
Estradiol 
Metformin 
Mesalazine 
Amoxicillin 
Acetyl salicylic 
acid 
Ofloxacin 
Propranolol 
Carbamazepine 
Furosemide 
Clarithromycin 
Diclofenac 
Sertraline 
Fluoxetine 
Erythromycin 
Oxytetracycline 
Sulfamethoxazole 
Fluoxetine 
Nitroglycerin 
Clofibrate 
Ibuprofen 
Acetominophen 
Estradiol 
Diclofenac  
Caffeine 
Ethyinylestradiol 
Atovaquone 
Sertraline 
Estradiol 
Mycophenolate 
mofetil 
Propranolol 
Acetylsalicylic acid 
Naproxen 
Felodipine  
Ketoconazole 
Amoxicillin 
Cephalexin 
Clavulanic 
acid 
Penicillin 
Trimethopri
m 
Sulfametho
xazole 
Azithromyc
in 
Amoxicillin 
Apramycin 
Bromhexine 
Ciprofloxacin 
Diclazuril 
Dihydrostrepto
mycin sulfate 
Doxycycline 
Enramycin 
Erythromycin 
Fenbendazole 
Amoxicillin 
Atenolol 
Hydrochlorothi
azide 
Ranitidine 
Clarithromycin 
Ceftriaxone 
Furosemide 
Bezafibrate 
Ciprofloxacin 
Enalapril 
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Disulfiram 
Oxytetracycline 
 
Omeprazole 
Orlistat 
Fenofibrate 
Paroxetine 
Fluvoxamine 
 
Carvedilol 
Metronidazole 
Trimethoprim 
Tetracycline 
Propranolol 
Gemfibrozil 
Naproxen 
Diazepam 
Paroxetine 
Clarithromycin 
Acetaminophen 
Amitriptyline 
Fluoxetine 
Dipyridamole 
Chlorprothixene 
Bromhexine 
Entacapone 
Fulvestrant 
Galantamine 
 
Erythromyc
in 
Florfenicol 
Fluvalinate 
Ivermectin 
Monensin 
sodium 
Norfloxacin 
Oxytetracycline 
 
Spiramycin 
Omeprazole 
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